Navigation Links
The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan
Date:3/18/2009

for critical diseases like cancer and diabetes, whose incidence is increasing due to Europe's ageing population. Subsequently, the patent expiries of key product classes and an increasing emphasis on cost containment are motivating governments to switch to affordable alternatives. Thus, there exists tremendous growth opportunity for biosimilar manufacturers.

However, the development of biosimilars is riddled with complexities, ranging from R&D and manufacturing to marketing. Their development remains one of the most expensive propositions in the pharmaceutical industry. In addition, meeting the stringent regulatory norms set by the European Medicines Agency (EMEA) will be an arduous exercise.

The current average cost of bringing a biosimilar to market is around $100-$200 million, in addition to a development period ranging from eight to ten years. This is approximately equivalent to the same for a biopharmaceutical product. Marketing presents another key challenge as, typically, there is initial resistance from the physician community.

"The most significant challenge, however, will be in proving similarity with the reference product as per the EMEA standards," adds Kambhammettu. "This is because the entire process involves large-scale clinical trials as well as the documentation and submission of immense volumes of data."

Pricing will be a key factor to recover the high level of investment that is required to develop and manufacture biosimilars. In addition, marketing strategies will have to be very different from generic drugs.

"While pricing a biosimilar, manufacturers must assess various factors such as the nature of the market, product class, level of competition and reimbursement structure," advises Kambhammettu. "As current biosimilars are marketed in the hospital sector, manufacturers must focus their marketing efforts on specialists to increase the probability of succes
'/>"/>

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BIOLOCK(TM) USA Launches Affordable Fingerprint door Locks for Homes and Offices
2. DNA 11, Creators of DNA Art, Introduces a More Affordable Line of Custom Portraits for this Year's Gift Giving Season
3. ZhenSpa.com provides Spa Enthusiasts Affordable Alternatives for Expensive Spa Treatments
4. Secretropin(R) - Effective, Preferable, Affordable as an Alternative to Injectable Growth Hormone - Gains Momentum
5. Biogenerics Legislation Provides Critical Pathway to Affordable Access for Patients with Chronic and Complex Conditions
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
10. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
11. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)...  Together with its customers, Elekta raised EUR 30,575 ... Barcelona . The funds will be donated ... to improve cancer care, specifically radiation oncology care, around ... patient should be denied potentially life-saving treatment simply because ... hospitals and clinics around the world to take care ...
(Date:4/24/2015)... AZ (PRWEB) April 24, 2015 The ... State University (ASU) have entered into an agreement to ... A memorandum of agreement signed by the universities will ... student success and other services particularly, though not exclusively, ... “We have complementary strengths and a similar set of ...
(Date:4/24/2015)... 24, 2015  Pfenex Inc. (NYSE MKT: PFNX) a ... therapeutics including high value and difficult to manufacture proteins, ... of 6,000,000 shares of its common stock at a ... the shares being offered, 2,610,000 are being offered by ... by existing stockholders. Pfenex will not receive any proceeds ...
(Date:4/24/2015)... Seoul Semiconductor announced the expansion of its ... lighting market. In recent months, there have ... emerging markets such as Russia, South America, and ... such as streetlight and area lighting, tunnel lighting, ... in 2005 the Acrich technology from Seoul Semiconductor ...
Breaking Biology Technology:Elekta helps raise $33,000 to bring radiation treatment to developing countries 2Elekta helps raise $33,000 to bring radiation treatment to developing countries 3South Dakota Mines, Arizona State University Pave Way for Cooperative Research 2Pfenex Inc. Announces Pricing Of Follow-on Offering 2Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2
... Tagging Vector for Gene Expression in Mammalian Cells , ... Tanya Hosfield Quinn Lu ,Stratagene , , The ... gene,expression in mammalian cells. A target gene inserted into ... epitope ,(N-terminal, C-terminal or ...
... new SmartPower 4000 power supply is an all-purpose power supply , Douglas Drake ... , , ... Power, Supply, Stratagene has ... supply, an all-in-one power supply for any, electrophoretic application. The ...
... ,,,,, A powerful method to detect protein ... Cathy Chang ,Stratagene , With Stratagenes mammalian ... to detect protein-protein interactions via the activation,of reporter ... of,reconstitution of a functional transcription factor caused by ...
Cached Biology Technology:An Epitope Tagging Vector for Gene Expression in Mammalian Cells 2An Epitope Tagging Vector for Gene Expression in Mammalian Cells 3An Epitope Tagging Vector for Gene Expression in Mammalian Cells 4An Epitope Tagging Vector for Gene Expression in Mammalian Cells 5An Epitope Tagging Vector for Gene Expression in Mammalian Cells 6A Versatile Power Supply for All Electrophoresis Applications 2A Versatile Power Supply for All Electrophoresis Applications 3A Versatile Power Supply for All Electrophoresis Applications 4A Versatile Power Supply for All Electrophoresis Applications 5New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 2New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 3New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 4New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 5New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 6New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 7New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 8New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 9
(Date:4/2/2015)... According to preliminary estimates Fingerprint ... higher than 125 MSEK. This exceeds the guidance provided ... revenues for Q1 2015 would be in line with ... 2014. The operating result for the first quarter is ... report will as previously communicated be published on May ...
(Date:4/1/2015)... 2015   Medisafe ™, the leading global medication ... iOS and Android smartphones and tablets, ... the platform to allow patients to track and correlate ... time, patients will be able to visualize in real-time ... biometrics, such as glucose levels and blood pressure. ...
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... of the "Global Gesture Recognition Market in Automotive ... The analysts forecast the Global Gesture Recognition market in ... over the period 2013-2018. Gesture recognition is ... to different gestures of an individual. Gesture recognition technology ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... Many people with schizophrenia have marked problems with ... behavior. These negative symptoms of schizophrenia can be ... For many years it was thought this ... associated with successful goal attainment. However, recent laboratory ...
... Ashley Ballantyne models the influence of Arctic sea ... His research was published in the Research Highlight ... The full paper will be published in ... Geosciences ., Ballantyne and coauthors from Northwestern University, ...
... , July 10, 2013  Polymer Technology Systems, Inc. ... family of point-of-care diagnostic products, has announced the ... 8,257,654 relates to the management of health data collected ... U.S. Patent No. 8,307,531 covers a method and apparatus ...
Cached Biology News:Calculating the value of effortful behavior: A clue to schizophrenia-related disability? 2PTS, Inc. Announces Two New Patents 2
Request Info...
Ultra-sensitive, non-radioactive measurement of COX-I and COX-II activity...
Recombinant Ovine (Sheep) Growth Hormone, Ultra Pure...
Mouse Granzyme D MAb (Clone 190617)...
Biology Products: